Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 1, 2003, Pages 36-42

  Ekborn, Andreas ^a   Lindberg, Annika ^a   Laurell, Göran ^a   Wallin, Inger ^a   Eksborg, Staffan ^a,b   Ehrsson, Hans ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cisplatin; Monohydrated complex of cisplatin; Nephrotoxicity; Ototoxicity; Pharmacokinetics

Indexed keywords

CISPLATIN; CREATININE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GUINEA PIG; HEARING; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; TITRIMETRY; TOXICITY TESTING; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CISPLATIN; CREATININE; EAR, INNER; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GUINEA PIGS; KIDNEY; MALE;

EID: 0037222523     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0540-5     Document Type: Article

References (36)

1. Andersson A, Ehrsson H (1994) Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J Chromatogr 652:203
2. Andersson A, Hedenmalm H, Elfsson B, Ehrsson H (1994) Determination of the acid dissociation constant for cis-diammineaquachloroplatinum(II) ion. A hydrolysis product of cisplatin. J Pharm Sci 83:859
3. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H (1996) Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci 85:824
4. 2+ in aqueous solution. Inorganica Chim Acta 70:87
5. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355
6. Borg E, Engstrom B (1983) Hearing thresholds in the rabbit. A behavioral and electrophysiological study. Acta Otolaryngol 95:19
7. Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123
8. Comis RL (1994) Cisplatin: The future. Semin Oncol 21:109
9. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russel AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623
10. Daley-Yates PT, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33:3063
11. Dunne A (1985) JANA: A new iterative polyexponential curve stripping program. Comput Methods Programs Biomed 20:269
12. Ehrsson HC, Wallin IB, Andersson AS, Edlund PO (1995) Cisplatin, transplatin and their hydrated complexes: Separation and identification using porous graphitic carbon and electro-spray ionization mass spectrometry. Anal Chem 67:3608
13. Ekborn A, Laurell G, Andersson A, Wallin I, Eksborg S, Ehrsson H (2000) Cisplatin-induced hearing loss: Influence of the mode of drug administration in the guinea pig. Hear Res 140:38
14. Ekborn A, Laurell G, Johnström P, Wallin I, Eksborg S, Ehrsson H (2002) D-methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear Res 165:53
15. 2+. Inorganic Chem 26:997
16. Finley RS, Fortner CL, Grove WR (1985) Cisplatin nephrotoxicity: A summary of preventative interventions. Drug Intell Clin Pharm 19:362
17. Gralla RJ (1998) Antiemetic therapy. Semin Oncol 25:577
18. Grigsby PW, Herzog TJ (2001) Current management of patients with invasive cervical carcinoma. Clin Obstet Gynecol 44:531
19. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C (1999) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83:866
20. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum-induced toxicities and therapeutic index: Mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584
21. Johnson NP, Hoeschele JD, Rahn RO (1980) Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 30:151
22. Jones MM, Basinger MA, Beaty JA, Holscher MA (1991) The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol 29:29
23. Kelman AD, Peresie HJ (1979) Mode of DNA binding of cis-platinum(II) antitumor drugs: A base sequence-dependent mechanism is proposed. Cancer Treat Rep 63:1445
24. Klis SFL, O'Leary SJ, Wijbenga J, de Groot JCMJ, Hamers FPT, Smoorenburg GF (2002) Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to cisplatin dose. Hear Res 164:138
25. Laurell G, Engstrom B (1989) The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hear Res 38:27
26. Laurell G, Jungnelius U (1990) High-dose cisplatin treatment: Hearing loss and plasma concentrations. Laryngoscope 100:724
27. Laurell G, Andersson A, Engstrom B, Ehrsson H (1995) Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother Pharmacol 36:83
28. Litterst CL (1981) Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61:99
29. Lokich J (2001) What is the "best" platinum: Cisplatin, carboplatin, or oxaliplatin? Cancer Invest 19:756
30. Meech RP, Campbell KC, Hughes LP, Rybak LP (1998) A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear Res 124:44
31. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19
32. 2O entry in endolymph, perilymph, and cerebrospinal fluid of the rat. Am J Physiol 243:F173
33. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269
34. Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M (2001) Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 51:371
35. Yachnin JR, Wallin I, Lewensohn R, Sirzen F, Ehrsson H (1998) The kinetics and cytotoxicity of cisplatin and its monohydrated complex. Cancer Lett 132:175
36. Zheng H, Fink D, Howell SB (1997) Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin. Clin Cancer Res 3:1157